ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

16 Tips from 16 Years Sick

Fibromyalgia Fare Fit for All Seasons

Tangerine Oil: A Citrusy Essential Oil With Well-Rounded Uses

New Study Shows Artificial Sweeteners Lead to Diabetes

Essential Oils — An Effective and Healthy Option to Treat Headaches

Antioxidant treatment could halt neurodegeneration in early Parkinson's

Higher vitamin D levels associated with less severe disease in NAFLD patients

Krill Oil: Make This Omega-3 Supplement Part of Your Health Regimen

How zinc helps fight esophageal cancer

Everything You Need to Know About Black Cohosh

 
Print Page
Email Article

Large New Study Supports Statins For Alzheimer's Disease

  [ 188 votes ]   [ Discuss This Article ]
www.ProHealth.com • April 28, 2004


Large New Study Supports Statins For Alzheimer's Disease; Nymox -NASDAQ: NYMX- Has Global Patent Rights for the Use of Statin Drugs for the Treatment and Prevention of Alzheimer's Disease MAYWOOD, N.J.--(BUSINESS WIRE)--April 28, 2004--A large new study has found strong further evidence that statin drugs have therapeutic benefit for Alzheimer's Disease (AD). Statin drugs are widely used cholesterol-lowering drugs. Researchers from France presented these significant new findings at the American Academy of Neurology meeting this week in San Francisco. Investigators followed 342 Alzheimer's disease patients for 35 months to determine whether taking statin and/or fibrates to lower cholesterol would have an effect on their rate of cognitive decline. They found that taking the cholesterol-lowering agents was associated with a slower cognitive decline and suggested that they may have a therapeutic benefit by a mechanism independent from the cholesterol-lowering action. The study, "Effects of Statins and Fibrates on Progression of Cognitive Decline in Alzheimer's Disease," was authored by Isabelle Masse, Regis Bordet, Dominique Deplanque, Abdullatif Al Khedr, Christian Libersa, and Florence Pasquier. Nymox Pharmaceutical Corporation (NASDAQ: NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD. According to Dr. Michael Munzar, Medical Director of Nymox, "Statin drugs have huge potential for Alzheimer's disease. They are safe, well tolerated and widely available. This large new study again supports the considerable body of evidence showing that taking statin drugs has positive effects on cognition in the elderly and can reduce the risk of Alzheimer's disease." A growing body of scientific and clinical studies have shown the potential benefits of statin drugs to prevent or treat AD. Studies have shown up to 70% reduction in AD incidence in individuals who use statin drugs. Recent studies include, for example, Neuroepidemiology 2004; 23:94-8; Neuron 2004; 41:7-10; Arch Neurol 2000; 57:1439-1443; Lancet 2000; 356:1627-1631; Arch Neurol 2002; 59:223-227; J Gerontol Biol Sci Med Sci 2002;57:M414-M418; and J Am Geriatr Soc 2002;50:1852-1856. The current global market for statins is estimated at $19 billion per year and to be growing at 15% per year. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.




Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Energy NADH™ 12.5mg Ultra ATP+, Double Strength


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

How One Tiny Molecule Turned into One Huge Health Breakthrough How One Tiny Molecule Turned into One Huge Health Breakthrough
Green Coffee Extract: Unique Obesity Intervention Green Coffee Extract: Unique Obesity Intervention
Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health
Looking for Energy? Turn to Plants. Looking for Energy? Turn to Plants.
Running on Empty? Fuel Up with NADH Running on Empty? Fuel Up with NADH

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map